A Novel Biomarker Discovery Strategy Combining Primary Tumour Xenograft Models and Glyco-Capture of Secreted Proteins

结合原发性肿瘤异种移植模型和分泌蛋白的糖捕获的新型生物标志物发现策略

• 批准号: 290638
• 负责人: Kislinger Thomas
• 金额: $ 25.61万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-09-01 至 2016-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=290638&lang=en
• 关键词: Biomarker; Ovarian Cancer; Proteomics; Recurrence; Xenograft

Epithelial ovarian cancer (EOC) is among the most common malignancies in women worldwide. In 2009, there were an estimated 21,000 new cases in North America, and it was the 5th leading cause of cancer-mortality in women. As for most cancers, disease stage

卵巢上皮癌(EOC)是世界范围内最常见的女性恶性肿瘤之一。2009年，北美估计有2.1万个新病例，是导致女性癌症死亡的第五大原因。至于大多数癌症，疾病分期